NEW YORK and HERZLIYA-PITUACH, Israel, May 5, 2014 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals Inc. (OTCQX: IMNP) (Nasdaq:IMNP) (“Immune” or the “Company”) announces its clinical trial and commercialization strategy for AmiKet, a topical drug for the treatment of Neuropathic Pain, pursuant to which the Company is ready to advance to phase 3 clinical trials, based on nine clinical trials in a total of 1700 patients. AmiKet is a topical combination of amitryptiline and ketamine designed to reduce the pain of patients with Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN) and Chemotherapy Induced Neuropathic Pain (CIPN).
Help employers find you! Check out all the jobs and post your resume.
